Measles Outbreak in Africa—Is There a Link to the HIV-1 Epidemic? by Nilsson, Anna & Chiodi, Francesca
Opinion





1Department of Women and Child Health at Karolinska Institutet, Astrid Lindgrens Childrens Hospital, Stockholm, Sweden, 2Department of Microbiology, Tumour and
Cell Biology at Karolinska Institutet, Stockholm, Sweden
Measles remains an important cause of
child mortality, although the numbers of
measles-related deaths has decreased dur-
ing the last decade [1] through childhood
immunisation programmes and follow-up
measles vaccine campaigns. In 2005, the
World Health Organization (WHO) and
the United Nations Children’s Fund
(UNICEF) launched a global plan to
further reduce measles mortality in the
years 2006–2010 [2]. Despite these joint
efforts, an increased number of large and
deadly outbreaks of measles on the African
continent were reported, with the most
severe outbreaks in Chad, Nigeria, and
Zimbabwe. The current increase in mea-
sles cases has been attributed to a failure in
maintaining high measles vaccine cover-
age [3]. There are obviously several
factors of medical and social relevance to
take into consideration when trying to
explain the increased measles outbreaks in
Africa. In this article, our focus is to
highlight the possibility of a co-existing
link between the measles outbreaks and
pathological features of HIV-1 infection in
mothers and children, as the measles
outbreaks occurred in countries with a
high HIV-1 prevalence.
Passively acquired maternal antibodies
protect infants against measles until the
time of measles vaccination, which in most
developing countries is administered at 9
months of age. In 1992, an increased risk
of measles before 9 months of age was
reported in children born to mothers with
HIV-1 [4], which was suggested to be due
to lower levels of passively acquired
antibodies at birth [5]. In a recent study,
the level of measles antibodies were
followed from 6 weeks of age until 11
months in HIV-1-infected, HIV-1-ex-
posed non-infected (born to mothers with
HIV-1 but not HIV-1 positive), and HIV-
1-seronegative children [6]. By 6 months
of age, 91% and 83% of HIV-1-infected
and HIV-1-exposed non-infected children
had measles antibody levels of ,50 mIU/
mL (cut-off value for specific immune
response); 42% of HIV-1-negative chil-
dren, on the other hand, retained high
antibody levels at 6 months. These
findings confirm the previous observation
[5] of low titres of maternal antibodies
being transferred to infants of mothers
with HIV-1. Children born to mothers
with HIV-1 have a higher risk of contract-
ing early measles independently of wheth-
er they are themselves HIV-1 infected [5].
In a study from Zambia, co-infection with
HIV-1 and measles in children was shown
to more than double the risk of death in
measles during hospitalisation [7]. Deaths
due to measles infection occurred in
12.2% of the children with HIV-1 (median
age 12 months) as compared to 4.3% of
non-HIV-1-infected children (14 months).
Since the control of measles and HIV-1
relay on efficient CD8 T cell responses,
the increased morbidity observed in chil-
dren with HIV-1 upon measles infection
can be related to the shift in cytokine
profile from Th1 to Th2 occurring in these
young individuals and impairing T cell
responses to both pathogens [8]. A Th1 to
Th2 shift during the course of chronic
HIV-1 infection is associated with pro-
gression to AIDS [9], and measles virus
infection also suppresses the ability of T
cells to produce IL-12, thus hampering T
cell responses [10].
To reduce the risk of contracting
measles in areas with high HIV-1 preva-
lence, WHO recommended that infants
receive two doses of measles vaccine, at 6
and 9 months [11]. This regimen was
evaluated in Zambia [12] and results
published in 2008 showed that 59% of
children with HIV-1 were measles anti-
body positive after the first vaccine dose;
this number increased to 64% after the
second dose. Among HIV-1-exposed non-
infected children, 68% and 94% were
seropositive after the first and second
immunisation, respectively, and similar
figures were shown for control children
(62% and 92%). To further pinpoint the B
cell impairments leading to low antibody
levels after measles vaccination in children
with HIV-1, Nair [13] characterised early
antibody responses to measles following
vaccination at 9 months of age. Interest-
ingly, HIV-1 infection impaired IgG
responses after vaccination as well as the
development of high avidity measles
antibodies. In a study from Kenya,
antibody titres to measles were evaluated
2 to 5 years after measles immunisation
received during the first year of life [14].
Several years after immunisation, only
33% of the children with HIV-1 main-
tained measles IgG antibodies, indicating
impairment in the establishment and the
maintenance of serological memory re-
sponses.
Which, then, could be the mechanism
accounting for the decreased amount of
measles antibodies circulating in mothers
with HIV-1 and poor response to measles
vaccination in children with HIV-1? The
rapid IgM immune response towards
measles occurring to a great extent in the
splenic marginal zone B cells is an
important first-line defence upon natural
infection and after immunisation. In
healthy children, the splenic marginal
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age [15], and this observation explains the
low responses observed upon vaccination
in young children. During HIV-1 infec-
tion, the structure of lymphoid tissue is
altered, leading to follicular hyperplasia
and likely to impairment of marginal zone
responses [16].
We suggest that the decline of resting
memory B cells reported by us [17–19]
and others [20] that occurs during HIV-1
infection may be an important pathogenic
mechanism linked to the low level of
measles-specific antibodies found in moth-
ers with HIV-1 and their children
(Figure 1). Memory B cells are responsible
for mounting and maintaining an ade-
quate serological response to antigens
previously encountered in life through
natural infection or vaccination. The
decline in B cells carrying immunological
memory correlated to loss of antibody
titres to measles, tetanus, and pneumococ-
cal antigens [17,18]. Interestingly, in turn,
the decline of serum measles antibodies
correlated to a decreased number of
measles-specific memory B cells in blood.
The antibody levels to pneumococcal
antigens were dramatically reduced al-
ready from primary HIV-1 infection [17].
Our studies on the loss of memory B cells
strongly suggest that this pathogenic mech-
anism may be causing a reduced level of
protective anti-measles antibodies in moth-
ers with HIV-1; it is also very likely that the
levels of measles antibodies in breast milk of
mothers with HIV-1 may be reduced in
comparison to that of healthy women. The
loss of memory B cells was positively
correlated to the number of CD4+ T cells,
a pivotal hallmark of immune deficiency
during HIV-1 infection [17]. It is likely that
an increased number of CD4+ T cells
following highly active antiretroviral thera-
py (HAART) may lead to a new generation
of measles-specific memory B cells through
repeated antigenic exposure in countries
with high measles prevalence.
Active HIV-1 replication correlates to
the lack of development of an adequate
serological memory as measured by the
poor response to measles vaccination
occurring in children with HIV-1 [21].
We showed that HAART treatment
administered early after birth led to
control of HIV-1 replication and also
preserved the evolution of the memory B
cell compartment and the likelihood of
response to childhood vaccines. In chil-
dren treated after 1 year of age, a decline
in memory B cells was observed, accom-
panied by a modest response to measles
vaccination. When matched with the
measles vaccination studies conducted in
developing countries, our findings indicate
that a low level of protective measles
antibodies in children with HIV-1, result-
ing from the impaired incapacity to mount
serological memory, may represent the
cause of measles outbreaks in countries
with high levels of HIV-1 infection.
It is encouraging that measles catch-up
vaccination programmes have been shown
to reduce measles morbidity and mortality
in southern Africa, although children born
to mothers with HIV-1 remained highly
susceptible to measles infection and its
lethal consequences [22]. In conclusion,
the recommended vaccination schedule to
eradicate measles may be inadequate in
countries with a high proportion of adults
and children with HIV-1. According to
the findings presented in this article, we
propose that HAART should be adminis-
tered to children and adults with HIV-1
prior to measles vaccination since
HAART improves the capacity to estab-
lish long-term serological memory and
maintain memory B cell responses in
individuals with HIV-1.
Figure 1. Maintenance and formation of measles-specific antibodies and memory B cells in mother and child. (A) In the non-infected
mother, a normal number of memory B cells produce a protective level of measles specific antibodies, which are transmitted to the child via the
placental barrier. In addition, the child will respond to measles vaccination by producing memory B cells and specific antibodies. (B) The HIV-1-
infected mother loses a large number of memory B cells as a result of pathogenic mechanisms linked to HIV-1 infection; this phenomenon leads to a
reduced amount of measles-specific antibodies in the mother and a low level of transmitted antibodies to the child. The HIV-1-exposed, non-infected
child, is, however, competent to respond to measles vaccination by generating protective levels of measles antibodies and measles-specific memory
B cells. (C) As a consequence of HIV-1 infection, both the HIV-1-infected mother and child lose measles-specific memory B cells formed upon measles
natural infection or vaccination. This leads to a low, non-protective level of measles antibodies in the mother, a low level of antibodies transmitted
through the placental barrier to the child, and a low, non-protective level of measles-specific antibodies produced from the infected child upon
vaccination.
doi:10.1371/journal.ppat.1001241.g001
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